Reuters logo
BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
April 27, 2017 / 11:29 AM / 8 months ago

BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test

April 27 (Reuters) - Myriad Genetics Inc:

* Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment

* Says financial terms of deal were not disclosed.

* Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below